A company using computer analysis of heart scans will report quarterly results Nov. 12.
Heartflow, Inc. (Nasdaq: HTFL) will report Q3 2026 earnings on Nov. 12, with a conference call at 4:30 p.m. ET. The company's AI technology for diagnosing coronary artery disease is used by 1,800 institutions globally and supported by 625 peer-reviewed studies. Heartflow's solutions are validated against invasive gold standards and improve patient outcomes.
How this was made
The 30-second read
Why it matters
The announcement sets a clear timeline for traders to position ahead of the earnings, likely increasing volume and volatility on Nov 12.
Market read
Earnings dates are standard catalysts; this adds a new, time‑specific event for HTFL.
What to watch
Potential regulatory or reimbursement changes for AI diagnostics could outweigh the earnings numbers.
Background
Heartflow is a Nasdaq‑listed AI company focused on coronary artery disease diagnostics. The press release announces its upcoming Q3 2026 earnings call.
Ticker impact
Heartflow announced the date and time for its Q3 2026 earnings release on Nov 12, 2026.
potential price swing around the after‑hours release, direction dependent on the earnings surprise.
Earnings dates are material events for a listed biotech; traders typically trade the upcoming release.
Market effects
May affect other AI‑driven health‑tech stocks as investors gauge sector momentum.
Primarily U.S. market impact; limited regional effect.
Modest global relevance given Heartflow's niche market.
Counterpoint
If the market has already priced in strong growth, the earnings could disappoint and trigger a sell‑off.
Key entities
- companyHeartflow, Inc.
AI-driven cardiovascular diagnostics firm (Nasdaq: HTFL).
